Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection

Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection

Abstract The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been shown to inhibit the BCR signal transduction pathway and cytokine production in B cells (Park et al. Arthritis Res. Ther. 18, 91, https://doi.org/10.1186/s13075-016-0988-z , 2016). This study describes the translation...

Full description

Bibliographic Details
Main Authors: Joo-Yun Byun, Yi T. Koh, Sun Young Jang, Jennifer W. Witcher, Jason R. Chan, Anna Pustilnik, Mark J. Daniels, Young Hoon Kim, Kwee Hyun Suh, Matthew D. Linnik, Young-Mi Lee
Format: Article
Language:English
Published: Nature Portfolio 2021-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-98255-7

Internet

https://doi.org/10.1038/s41598-021-98255-7

Similar Items